The abstract is read at the publisher; the summary is JClub's.
Dual-platform plasma proteogenomics prioritizes GSTA1 and ARG1 as druggable cross-domain proteins in cardiovascular-kidney-metabolic syndrome, supported by strong cross-platform concordance and colocalization.
- Why it matters: CKM syndrome spans metabolic, renal, and cardiovascular biology, but circulating proteins with genetically supported effects across multiple domains are not well defined.
- What they did: Using cis-pQTL instruments from UKB-PPP (2,030 proteins) and deCODE (1,640 proteins), the study applied two-sample Mendelian randomization across seven CKM outcomes, then used colocalization and single-cell expression mapping to prioritize proteins.
- The result: Six cross-domain proteins were found, with GSTA1 colocalizing with eGFR (posterior probability 0.97) and ARG1 with BMI (0.93); both were small-molecule tractable, with GSTA1 inhibitor-bound structure PDB 1GSF and low-micromolar chemotypes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.